VIR-7831 for the Early Treatment of COVID-19 in Outpatients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,057

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

September 2, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

VIR-7831 (sotrovimab)

VIR-7831 (sotrovimab) given by intravenous infusion (single dose)

DRUG

Placebo

Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)

Trial Locations (91)

1090

Investigative Site, Vienna

1100

Investigative Site, Vienna

7016

Investigative Site, Bellavista

10456

Investigative Site, The Bronx

15007

Investigative Site, El Agustino

15036

Investigative Site, San Isidro

15082

Investigative Site, Lima

15131

Investigative Site, Huaral

15478

Investigative Site, Smithfield

17005

Investigative Site, Girona

18014

Investigative Site, Granada

21230

Investigative Site, Baltimore

27203

Investigative Site, Asheboro

28208

Investigative Site, Charlotte

30030

Investigative Site, Decatur

30281

Investigative Site, Stockbridge

30315

Investigative Site, Atlanta

30318

Investigative Site, Atlanta

32607

Investigative Site, Gainesville

33016

Investigative Site, Hialeah

33024

Investigative Site, Pembroke Pines

33027

Investigative Site, Miramar

33064

Investigative Site, Pompano Beach

33122

Investigative Site, Miami

33125

Investigative Site, Miami

33155

Investigative Site, Miami

33157

Investigative Site, Palmetto Bay

33166

Investigative Site, Doral

33169

Investigative Site, North Miami

33173

Investigative Site, Miami

33186

Investigative Site, Miami

33614

Investigative Site, Tampa

33615

Investigative Site, Tampa

35055

Investigative Site, Cullman

36207

Investigative Site, Anniston

36312

Investigative Site, Vigo

37421

Investigative Site, Chattanooga

43215

Investigative Site, Columbus

46544

Investigative Site, Mishawaka

48723

Investigative Site, Caro

63042

Investigative Site, Hazelwood

70072

Investigative Site, Marrero

70601

Investigative Site, Lake Charles

75126

Investigative Site, Forney

75149

Investigative Site, Mesquite

75231

Investigative Site, Dallas

76210

Investigative Site, Denton

77017

Investigative Site, Houston

77024

Investigative Site, Houston

77058

Investigative Site, Houston

77090

Investigative Site, Houston

77338

Investigative Site, Humble

77478

Investigative Site, Sugar Land

77521

Investigative Site, Baytown

77702

Investigative Site, Beaumont

78041

Investigative Site, Laredo

78504

Investigative Site, McAllen

78705

Investigative Site, Austin

79935

Investigative Site, El Paso

83404

Investigative Site, Idaho Falls

85210

Investigative Site, Mesa

85712

Investigative Site, Tucson

87505

Investigative Site, Santa Fe

89109

Investigative Site, Las Vegas

89130

Investigative Site, Las Vegas

90017

Investigative Site, Los Angeles

90036

Investigative Site, Los Angeles

90274

Investigative Site, Rolling Hills Estates

91325

Investigative Site, Northridge

93030

Investigative Site, Oxnard

95817

Investigative Site, Sacramento

98034

Investigative Site, Kirkland

98109

Investigative Site, Seattle

30110-934

Investigative Site, Belo Horizonte

87083-240

Investigative Site, Maringá

590250-50

Investigative Site, Natal

99010-120

Investigative Site, Passo Fundo

90020-090

Investigative Site, Porto Alegre

90035-903

Investigative Site, Porto Alegre

89801-355

Investigative Site, Chapecó

13060-904

Investigative Site, Campinas

09030-010

Investigative Site, Santo André

05615-190

Investigative Site, Vila Assuncao

N7T 4X3

Investigative Site, Sarnia

M9V 4B4

Investigative Site, Toronto

G2J0C4

Investigative Site, Québec

07006

Investigative Site, Bella Vista

08540

Investigative Site, Centelles

08221

Investigative Site, Terrassa

02006

Investigative Site, Albacete

BT7 2EB

Investigative Site, Belfast

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Vir Biotechnology, Inc.

INDUSTRY

NCT04545060 - VIR-7831 for the Early Treatment of COVID-19 in Outpatients | Biotech Hunter | Biotech Hunter